Clinical trial
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
NCT03860272
Study timeline
Study start (actual)2019-03-20Date precision: day
Registry last updated2026-03-30
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Advanced Cancerunresolved
Angiosarcomaunresolved
Endometrial Cancerunresolved
Fibrolamellar Carcinomaunresolved
Non-small-cell Lung Cancerunresolved
Ovarian Cancerunresolved
Prostate Cancerunresolved
Interventions
BotensilimabDRUG
BalstilimabDRUG
Sponsors & collaborators
Agenus Inc.lead sponsor
Mapped research locations
New YorkNew York, United States3Los AngelesCalifornia, United States3BostonMassachusetts, United States2HoustonTexas, United States1MiamiFlorida, United States1San AntonioTexas, United States1LondonUnited Kingdom1PortlandOregon, United States1AuroraColorado, United States1New HavenConnecticut, United States1ScottsdaleArizona, United States1DuarteCalifornia, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03860272 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.